There has been a thorough assessment of ganetespib activity in breast cancer cell lines involving luminal and basal tissues, hormone receptor subtypes, HER2-positive cancer, TNBC (triple-negative breast cancer), and inflammatory breast cancer (IBC). This evidence concerns the gene ERBB2 and inflammatory breast carcinoma.